Press release
Hyperuricemia Drugs Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth
Hyperuricemia Drugs
How Large Will the Hyperuricemia Drugs Market Size By 2025?
The market for hyperuricemia medications has witnessed a significant expansion in recent years. It is poised to increase from $4.75 billion in 2024 to $5.16 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.5%. This growth during the historic period can be linked to factors such as the escalating incidence of gout, scarce treatment alternatives, a burgeoning elderly population, inactive lifestyles, and enhanced awareness about hyperuricemia.
How Big Is the Hyperuricemia Drugs Market Size Expected to Grow by 2029?
The market for hyperuricemia drugs is predicted to witness substantial growth over the coming years. Projected to reach a value of $7.07 billion by 2029, it will expand at a compound annual growth rate (CAGR) of 8.2%. Factors such as a surge in chronic kidney disease cases, priority on early diagnosis, rising demand for tailor-made medicine, creation of innovative drug formulations, and escalating healthcare spending are driving this growth. Key trends forecasted during this period comprise a heightened emphasis on precision medicine, an increase in combined therapies' usage, new developments in non-invasive treatments, a heightened focus on the safety and effectiveness of the drugs and progression in the study of pharmacogenomics.
View the full report here:
https://www.thebusinessresearchcompany.com/report/hyperuricemia-drugs-global-market-report
Which Key Market Drivers Powering Hyperuricemia Drugs Market Expansion and Growth?
The surge in hyperuricemia and gout occurrences is predicted to fuel the hyperuricemia drug market's expansion. Hyperuricemia is a medical condition where there is an excess of uric acid in the bloodstream, potentially leading to gout, a painful arthritis type resulting from urate crystal accumulation in the joints. The prevalence of hyperuricemia and gout is influenced by factors such as genetic tendencies, dietary preferences particularly high purine consumption, obesity, kidney functionality, lifestyle decisions like alcohol usage and dehydration, certain drugs, and chronic illnesses including hypertension and diabetes. Hyperuricemia medicines play a crucial role in controlling uric acid concentrations, thus preventing hyperuricemia and gout growth by mitigating uric acid accumulation and lessening corresponding symptoms. For example, data from The Lancet, a UK-based general medical journal in July 2024, showed that globally, gout was 3.26 times more common in men than women in 2020, and its incidence increased with age, with around 95.8 million cases anticipated by 2050. Hence, the escalating occurrences of hyperuricemia and gout are propelling the hyperuricemia drug market's expansion.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19517&type=smp
Which Fast-Growing Trends Are Poised to Disrupt the Hyperuricemia Drugs Market?
Key players in the hyperuricemia drug marketplace, such as Lupin, are focusing on the development of cutting-edge products like therapeutic equivalent generic versions. These products provide an affordable alternative aimed at expanding patient access to gout treatment. Such generic versions have the identical active ingredients, identical dosage form, and are anticipated to give the same clinical impact and safety profile as the branded counterparts. For instance, Lupin, a pharmaceutical enterprise based in India, gained approval from the US health authority for its Febuxostat Tablets (40 mg and 80 mg) and Varenicline Tablets (0.5 mg and 1 mg) in January 2024. These generic medicines look forward to offering low-cost options for patients necessitating hyperuricemia treatment (Febuxostat) and smoking cessation assistance (Varenicline). Lupin, by providing these generic products, aims to enlarge the accessibility of crucial medications, gaining a fraction of the US pharmaceutical market and backing patients with economical alternatives for healthcare.
What Are the Emerging Segments in the Hyperuricemia Drugs Market?
The hyperuricemia drugsmarket covered in this report is segmented -
1) By Type: Asymptomatic Hyperuricemia, Symptomatic Hyperuricemia, Other Types
2) By Drugs: Nonsteroidal Anti-Inflammatory Drugs, Xanthine Oxidase Inhibitors, Selective Uric Acid Reabsorption Inhibitor (SURI), Uricosuric Agents, Other Drugs
3) By Diseases: Gout, Kidney Stone, Other Diseases
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Asymptomatic Hyperuricemia: Uric Acid Lowering Agents, Lifestyle Modification Supplements
2) By Symptomatic Hyperuricemia: Anti-Inflammatory Drugs, Uric Acid Inhibitors, Corticosteroids
3) By Other Types: Combination Therapy, Supportive Care Medications, Dietary Supplements
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19517&type=smp
Who Are the Global Leaders in the Hyperuricemia Drugs Market?
Major companies operating in the hyperuricemia drugs market are Pfizer Inc., Merck & Co., Bayer AG, Sanofi SA, Myers Squibb Bristol Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline PLC, Roche Holdings Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceuticals, Regeneron Pharmaceuticals Inc., Teijin Pharma Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Kissei Pharmaceutical Co. Ltd., Himalaya Wellness Company, Fuji Yakuhin Co. Ltd.
Which are the Top Profitable Regional Markets for the Hyperuricemia Drugs Industry?
North America was the largest region in the hyperuricemia drugs market in 2024. The regions covered in the hyperuricemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19517
"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperuricemia Drugs Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth here
News-ID: 4144835 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Hyperuricemia
Hyperuricemia Drugs Market Size, Share and Growth Report, 2034
" The hyperuricemia drug market is projected to reach a valuation of approximately $7.5 billion in 2024, driven by the rising prevalence of gout and escalating healthcare expenditures. The anticipated market growth for the period from 2025 to 2034 is expected to propel the market value to around $12 billion, reflecting an impressive Compound Annual Growth Rate (CAGR) of 5.4%. "
Exactitude Consultancy., Ltd. released a research report titled "Hyperuricemia Drugs…
What's Driving the Hyperuricemia Drugs Market 2025-2034: Rising Incidence Of Hyp …
What Are the Projections for the Size and Growth Rate of the Hyperuricemia Drugs Market?
The market size of drugs for hyperuricemia has seen robust growth in the past few years. The market is expected to expand from $4.75 billion in 2024 to $5.16 billion in 2025, displaying a compound annual growth rate (CAGR) of 8.5%. The historical growth can be credited to factors such as the escalating cases of gout,…
Hyperuricemia Market Statistical Forecast, Trade Analysis 2024 - 2031
DataM Intelligence has published a new research report on "Hyperuricemia Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hyperuricemia-market
The…
Hyperuricemia Drugs Market: Insights and Forecast | 2024-2030
Hyperuricemia Drugs Market Overview:
Maximize Market Research a business Analytics company has released a report on the "Hyperuricemia Drugs Market". As per the "Hyperuricemia Drugs report," the total market size value from 2023 and estimated value for 2030 with a CAGR forecasted from 2024 to 2030.
Projected Growth in Revenue:
The Hyperuricemia Drugs Market size was valued at USD 5.08 Billion in 2023 and the total Hyperuricemia Drugs Market revenue is expected to…
Hyperuricemia Market Analysis and Precise Outlook 2020-2030
Hyperuricemia Market Insights, Epidemiology, and Market Forecast-2030: The Hyperuricemia market report provides current treatment practices, emerging drugs, Hyperuricemia market share of the individual therapies, current and forecasted Hyperuricemia market Size from 2017 to 2030 segmented by seven major markets.
The report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom)…
Hyperuricemia-Pipeline Review H2 2018
Hyperuricemia-Pipeline Review, H2 2018
Summary
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia-Pipeline Review, H2 2018, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain…
